EUCRW (Eucrates Biomedical Acquisition) Tariff Resilience Score: 7/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EUCRW Eucrates Biomedical Acquisition Corp EUCRW
22 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Eucrates Biomedical Acquisition Tariff Resilience Score?

Eucrates Biomedical Acquisition EUCRW 22 Tariff Resilience Score is 7 as of Sep. 09, 2026. GuruFocus rates EUCRW with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Eucrates Biomedical Acquisition has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Eucrates Biomedical Acquisition has EUCRU, as a SPAC, has limited direct exposure to tariffs. However, its target acquisitions in the biomedical sector may face supply chain challenges, slightly reducing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Eucrates Biomedical Acquisition might have Highly Resilient.

Eucrates Biomedical Acquisition  (NAS:EUCRW) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Eucrates Biomedical Acquisition Tariff Resilience Score Related Terms

EUCRW vs FXCO, AEHA, LMAO: Tariff Resilience Score Comparison

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition Tariff Resilience Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Tariff Resilience Score falls into.


EUCRW
22GF Score
Eucrates Biomedical Acquisition Corp EUCRW
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Eucrates Biomedical Acquisition (EUCRW) has a Tariff Resilience Score of 7 as of Sep. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.
Is Eucrates Biomedical Acquisition's Tariff Resilience Score too high?
Eucrates Biomedical Acquisition's current Tariff Resilience Score is 7. Overall, Eucrates Biomedical Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Eucrates Biomedical Acquisition's Tariff Resilience Score compare to FXCO and AEHA?
Eucrates Biomedical Acquisition's Tariff Resilience Score of 7 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Diversified Financial Services company?
A good Tariff Resilience Score depends on the Diversified Financial Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Eucrates Biomedical Acquisition's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eucrates Biomedical Acquisition stock overvalued right now?
Eucrates Biomedical Acquisition (EUCRW) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7. Eucrates Biomedical Acquisition's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Eucrates Biomedical Acquisition (EUCRW), the current Tariff Resilience Score is 7 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eucrates Biomedical Acquisition Business Description

Address 250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Eucrates Biomedical Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EUCRW

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price